KALA
Kala Pharmaceuticals Inc
NASDAQ: KALA · HEALTHCARE · BIOTECHNOLOGY
$3.09
-6.28% today
Updated 2026-06-03
Market cap
$45.17M
P/E ratio
—
P/S ratio
23.75x
EPS (TTM)
$-102.01
Dividend yield
—
52W range
$2 – $1,030
Volume
2.4M
Kala Pharmaceuticals Inc (KALA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.84M | $-15.36M | $-15.09M | $-27.35M | $-34.10M | $-54.12M | $-92.72M | $-90.69M | $-108.23M | $-78.91M | $-27.93M | $-29.38M | $-31.99M |
| Capital expenditures | $789000.00 | $225000.00 | $252000.00 | $153000.00 | $480000.00 | $1.58M | $1.33M | $1.94M | $886000.00 | $313000.00 | $610000.00 | $208000.00 | $15000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | $638000.00 | $2.07M | $3.57M | $8.62M | $9.99M | $13.31M | $16.09M | $7.01M | $7.46M | $8.39M | $7.00M |
| Free cash flow | $-11.63M | $-15.59M | $-15.34M | $-27.50M | $-34.58M | $-55.70M | $-94.06M | $-92.64M | $-109.12M | $-79.22M | $-28.54M | $-29.59M | $-32.01M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | $0.00 | — | — | — | — | — | $365000.00 | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $69.12M | $68.41M | $-85.07M | $-8.28M | — | — | — | — | — |
Frequently asked questions
How much free cash flow does KALA generate?
KALA produced $-32.01M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is KALA's balance sheet healthy?
KALA holds $7.56M in cash and equivalents against — in long-term debt, on $7.00M of shareholder equity. That debt is best read against the cash flow the business throws off each year.